Kannalife Announces Completion of Name Change, Ticker Symbol Change
January 16, 2019 09:00 ET
|
Kannalife, Inc.
DOYLESTOWN, Pa., Jan. 16, 2019 (GLOBE NEWSWIRE) -- Kannalife, Inc. (“Kannalife”) (OTC: KLFE), a bio-pharmaceutical and phyto-medical company, is pleased to announce that the Company’s name change...
Kannalife Sciences Finalizes Share Exchange Agreement with TYG Solutions Corp.
August 01, 2018 08:00 ET
|
Kannalife Sciences, Inc.
NEW YORK, Aug. 01, 2018 (GLOBE NEWSWIRE) -- Kannalife Sciences, Inc. (“Kannalife”), a bio-pharmaceutical and phyto-medical company, is pleased to announce the completion of a share exchange...
Kannalife Sciences to be Featured in Dateline NBC Segment Covering Company’s Research on CBD-Like Molecules as Treatments for HE, CTE
May 18, 2018 09:00 ET
|
Kannalife Sciences, Inc.
NEW YORK, May 18, 2018 (GLOBE NEWSWIRE) -- Kannalife Sciences, Inc. (“Kannalife”), a bio-pharmaceutical and phyto-medical company, is excited to announce that the Company will be featured in a...
Kannalife Sciences CEO Dean Petkanas to Provide Presentation on Industry Advancement at 2018 Cannabinoids in Medicine Summit
April 27, 2018 10:00 ET
|
Kannalife Sciences, Inc.
NEW YORK, April 27, 2018 (GLOBE NEWSWIRE) -- Kannalife Sciences, Inc. (“Kannalife”), a phyto-medical company, announced today that the Company’s CEO Dean Petkanas will be presenting at the 2018...
Kannalife Sciences Announces Feasibility Study With Catalent Pharma Solutions for the Development of a Novel Cannabinoid Therapeutic Agent to Treat CTE and HE
February 29, 2016 09:00 ET
|
Kannalife, Inc.
NEW YORK, Feb. 29, 2016 (GLOBE NEWSWIRE) -- Kannalife Sciences, Inc. (“Kannalife”), a Phyto-Medical Company, is pleased to announce the progress of its ongoing feasibility study being performed by...
Kannalife Sciences Announces Publication of “Discovery of KLS-13019, a Cannabidiol-Derived Neuroprotective Agent, With Improved Potency, Safety and Permeability”
February 16, 2016 11:15 ET
|
Kannalife, Inc.
NEW YORK, Feb. 16, 2016 (GLOBE NEWSWIRE) -- Kannalife Sciences, Inc. (“Kannalife”), a Phyto-Medical Company, is pleased to announce the publication of the body of science behind KLS-13019, one of...
Kannalife Sciences Announces Publication of “Discovery of KLS-13019, a Cannabidiol-Derived Neuroprotective Agent, With Improved Potency, Safety and Permeability”
February 16, 2016 11:15 ET
|
Kannalife, Inc.
NEW YORK, Feb. 16, 2016 (GLOBE NEWSWIRE) -- Kannalife Sciences, Inc. (“Kannalife”), a Phyto-Medical Company, is pleased to announce the publication of the body of science behind KLS-13019, one of...
Kannalife Sciences, Inc. and Gridiron Cannabis Coalition, LLC Sign Binding Memorandum of Understanding
December 21, 2015 09:00 ET
|
Kannalife, Inc.
NEW YORK, Dec. 21, 2015 (GLOBE NEWSWIRE) -- Kannalife Sciences, Inc., a Phyto-Medical Company (“Kannalife”), announced the signing of a binding memorandum of understanding with Gridiron Cannabis...
KannaLife Sciences, Inc. Files PCT Patent Application for Novel Treatments for Neurodegenerative Disorders
January 23, 2015 10:09 ET
|
Kannalife, Inc.
HUNTINGTON, N.Y., Jan. 23, 2015 (GLOBE NEWSWIRE) -- Kannalife Sciences, Inc. ("KannaLife") announces that it has filed a non-provisional patent application entitled: "Novel Functionalized 1,3-Benzene...
KannaLife Sciences, Inc. and Kannaway, LLC Sign Long Term Sales, Marketing and Product Development Agreement
March 31, 2014 09:30 ET
|
Kannalife, Inc.
WEST HILLS, N.Y., March 31, 2014 (GLOBE NEWSWIRE) -- KannaLife Sciences, Inc. ("KannaLife") and Kannaway LLC ("Kannaway"), have entered into a five year sales, marketing and product development...